Boston Scientific Corporation $BSX Stock Holdings Lowered by Stance Capital LLC

Key Points

• Stance Capital LLC reduced its holdings in Boston Scientific Corporation by 11.3%, owning 41,897 shares valued at approximately $4.23 million after selling 5,358 shares.
• Boston Scientific recently reported quarterly earnings of $0.75 EPS, exceeding expectations and marking a 22.8% year-over-year revenue increase of $5.06 billion.
• Wall Street analysts maintain a consensus rating of "Buy" for Boston Scientific, with price targets rising to an average of $117.50 following several upgrades.

Stance Capital LLC decreased its stake in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 11.3% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 41,897 shares of the medical equipment provider's stock after selling 5,358 shares during the quarter. Boston Scientific comprises about 3.0% of Stance Capital LLC's portfolio, making the stock its 10th largest holding. Stance Capital LLC's holdings in Boston Scientific were worth $4,227,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Temasek Holdings Private Ltd boosted its position in shares of Boston Scientific by 167.0% during the first quarter. Temasek Holdings Private Ltd now owns 1,085,411 shares of the medical equipment provider's stock worth $109,496,000 after acquiring an additional 678,917 shares during the last quarter. Teza Capital Management LLC bought a new position in Boston Scientific during the first quarter valued at $1,457,000. Rise Advisors LLC lifted its position in Boston Scientific by 13.9% during the first quarter. Rise Advisors LLC now owns 844 shares of the medical equipment provider's stock valued at $85,000 after purchasing an additional 103 shares during the last quarter. Sandler Capital Management lifted its position in Boston Scientific by 18.8% during the first quarter. Sandler Capital Management now owns 41,782 shares of the medical equipment provider's stock valued at $4,215,000 after purchasing an additional 6,605 shares during the last quarter. Finally, PharVision Advisers LLC bought a new position in Boston Scientific during the first quarter valued at $384,000. Institutional investors own 89.07% of the company's stock.

Boston Scientific Stock Down 2.6%

Shares of Boston Scientific stock traded down $2.77 on Wednesday, reaching $105.32. The stock had a trading volume of 10,384,952 shares, compared to its average volume of 7,468,574. The company has a 50 day moving average price of $104.85 and a 200 day moving average price of $102.22. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. Boston Scientific Corporation has a 1 year low of $80.64 and a 1 year high of $109.50. The stock has a market capitalization of $156.06 billion, a P/E ratio of 62.69, a P/E/G ratio of 2.60 and a beta of 0.65.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The firm had revenue of $5.06 billion for the quarter, compared to the consensus estimate of $4.89 billion. During the same quarter in the previous year, the firm earned $0.62 EPS. The company's quarterly revenue was up 22.8% compared to the same quarter last year. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, equities research analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current year.

Insider Activity

In related news, Director Edward J. Ludwig sold 4,000 shares of Boston Scientific stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $106.03, for a total value of $424,120.00. Following the completion of the sale, the director directly owned 18,479 shares in the company, valued at $1,959,328.37. This trade represents a 17.79% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Arthur C. Butcher sold 17,313 shares of the business's stock in a transaction on Friday, August 1st. The shares were sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the sale, the executive vice president directly owned 23,600 shares in the company, valued at $2,469,268. This trade represents a 42.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 174,214 shares of company stock worth $18,397,457 in the last quarter. 0.50% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on BSX shares. Barclays increased their price target on Boston Scientific from $125.00 to $133.00 and gave the stock an "overweight" rating in a report on Thursday, July 24th. Jefferies Financial Group reaffirmed a "hold" rating on shares of Boston Scientific in a research report on Monday, July 21st. Royal Bank Of Canada reiterated an "outperform" rating on shares of Boston Scientific in a research report on Thursday, July 24th. Morgan Stanley lifted their target price on Boston Scientific from $120.00 to $125.00 and gave the stock an "overweight" rating in a research report on Friday, May 16th. Finally, Truist Financial lifted their target price on Boston Scientific from $120.00 to $125.00 and gave the stock a "buy" rating in a research report on Thursday, July 24th. Three investment analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and one has given a Hold rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $117.79.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.